The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: A single-center, prospective, open-label, observational study

Kyung Kgi Park, Seung Hwan Lee, Byungha Chung

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Introduction. The adverse effects of long-term drug therapy for prostate cancer (PCa) can dramatically impact patient quality of life and are considered to be important factors when selecting treatment. Aim. To assess stretched penile length before and after long-term androgen deprivation therapy (ADT) for treatment of PCa. Methods. From January 2008 to June 2010 at a single institution, 39 consecutive patients without distant metastases who were elected to receive ADT as initial therapy for PCa were prospectively enrolled. Exclusion criteria were history of penile anomalies and/or trauma, and prior radical prostate surgery or radiation therapy. Erectile functions were evaluated at baseline according to the International Index of Erectile Function (IIEF). Vertically stretched penile length was measured every 3 months from the pubopenile junction to the meatus with a spring scale. Main Outcome Measure. After ADT, significant 3-month interval changes in stretched penile length were noted for up to 15 months (P<0.001). The relationship between potency and penile shortening was not significant (P=0.45). Results. The mean patient age was 67.1 years. Before therapy, the mean stretched penile length was 10.76cm. After 24 months of ADT, mean penile length had decreased to 8.05cm. However, these changes plateaued after 15 months. Normal erectile function (EF) was reported by 41% of patients before therapy, while 10.5% reported normal EF at the 24-month follow-up. The relationship between potency and penile shortening was not significant. However, patients who preserved their potency tended to experience less penile shortening. Conclusions. The administration of luteinizing hormone-releasing hormone (LHRH) agonists induced significant decreases in penile length for only up to 15 months in the absence of the confounding effects of surgery and radiation.

Original languageEnglish
Pages (from-to)3214-3219
Number of pages6
JournalJournal of Sexual Medicine
Volume8
Issue number11
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Androgens
Observational Studies
Prostatic Neoplasms
Therapeutics
Radiation Effects
Gonadotropin-Releasing Hormone
Prostate
Radiotherapy
Quality of Life
Outcome Assessment (Health Care)
Neoplasm Metastasis
Drug Therapy
Wounds and Injuries

All Science Journal Classification (ASJC) codes

  • Reproductive Medicine
  • Obstetrics and Gynaecology
  • Urology

Cite this

@article{51c7a1181b5b4bd6a05ef273da31eb6b,
title = "The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer: A single-center, prospective, open-label, observational study",
abstract = "Introduction. The adverse effects of long-term drug therapy for prostate cancer (PCa) can dramatically impact patient quality of life and are considered to be important factors when selecting treatment. Aim. To assess stretched penile length before and after long-term androgen deprivation therapy (ADT) for treatment of PCa. Methods. From January 2008 to June 2010 at a single institution, 39 consecutive patients without distant metastases who were elected to receive ADT as initial therapy for PCa were prospectively enrolled. Exclusion criteria were history of penile anomalies and/or trauma, and prior radical prostate surgery or radiation therapy. Erectile functions were evaluated at baseline according to the International Index of Erectile Function (IIEF). Vertically stretched penile length was measured every 3 months from the pubopenile junction to the meatus with a spring scale. Main Outcome Measure. After ADT, significant 3-month interval changes in stretched penile length were noted for up to 15 months (P<0.001). The relationship between potency and penile shortening was not significant (P=0.45). Results. The mean patient age was 67.1 years. Before therapy, the mean stretched penile length was 10.76cm. After 24 months of ADT, mean penile length had decreased to 8.05cm. However, these changes plateaued after 15 months. Normal erectile function (EF) was reported by 41{\%} of patients before therapy, while 10.5{\%} reported normal EF at the 24-month follow-up. The relationship between potency and penile shortening was not significant. However, patients who preserved their potency tended to experience less penile shortening. Conclusions. The administration of luteinizing hormone-releasing hormone (LHRH) agonists induced significant decreases in penile length for only up to 15 months in the absence of the confounding effects of surgery and radiation.",
author = "Park, {Kyung Kgi} and Lee, {Seung Hwan} and Byungha Chung",
year = "2011",
month = "1",
day = "1",
doi = "10.1111/j.1743-6109.2011.02364.x",
language = "English",
volume = "8",
pages = "3214--3219",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "11",

}

TY - JOUR

T1 - The effects of long-term androgen deprivation therapy on penile length in patients with prostate cancer

T2 - A single-center, prospective, open-label, observational study

AU - Park, Kyung Kgi

AU - Lee, Seung Hwan

AU - Chung, Byungha

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction. The adverse effects of long-term drug therapy for prostate cancer (PCa) can dramatically impact patient quality of life and are considered to be important factors when selecting treatment. Aim. To assess stretched penile length before and after long-term androgen deprivation therapy (ADT) for treatment of PCa. Methods. From January 2008 to June 2010 at a single institution, 39 consecutive patients without distant metastases who were elected to receive ADT as initial therapy for PCa were prospectively enrolled. Exclusion criteria were history of penile anomalies and/or trauma, and prior radical prostate surgery or radiation therapy. Erectile functions were evaluated at baseline according to the International Index of Erectile Function (IIEF). Vertically stretched penile length was measured every 3 months from the pubopenile junction to the meatus with a spring scale. Main Outcome Measure. After ADT, significant 3-month interval changes in stretched penile length were noted for up to 15 months (P<0.001). The relationship between potency and penile shortening was not significant (P=0.45). Results. The mean patient age was 67.1 years. Before therapy, the mean stretched penile length was 10.76cm. After 24 months of ADT, mean penile length had decreased to 8.05cm. However, these changes plateaued after 15 months. Normal erectile function (EF) was reported by 41% of patients before therapy, while 10.5% reported normal EF at the 24-month follow-up. The relationship between potency and penile shortening was not significant. However, patients who preserved their potency tended to experience less penile shortening. Conclusions. The administration of luteinizing hormone-releasing hormone (LHRH) agonists induced significant decreases in penile length for only up to 15 months in the absence of the confounding effects of surgery and radiation.

AB - Introduction. The adverse effects of long-term drug therapy for prostate cancer (PCa) can dramatically impact patient quality of life and are considered to be important factors when selecting treatment. Aim. To assess stretched penile length before and after long-term androgen deprivation therapy (ADT) for treatment of PCa. Methods. From January 2008 to June 2010 at a single institution, 39 consecutive patients without distant metastases who were elected to receive ADT as initial therapy for PCa were prospectively enrolled. Exclusion criteria were history of penile anomalies and/or trauma, and prior radical prostate surgery or radiation therapy. Erectile functions were evaluated at baseline according to the International Index of Erectile Function (IIEF). Vertically stretched penile length was measured every 3 months from the pubopenile junction to the meatus with a spring scale. Main Outcome Measure. After ADT, significant 3-month interval changes in stretched penile length were noted for up to 15 months (P<0.001). The relationship between potency and penile shortening was not significant (P=0.45). Results. The mean patient age was 67.1 years. Before therapy, the mean stretched penile length was 10.76cm. After 24 months of ADT, mean penile length had decreased to 8.05cm. However, these changes plateaued after 15 months. Normal erectile function (EF) was reported by 41% of patients before therapy, while 10.5% reported normal EF at the 24-month follow-up. The relationship between potency and penile shortening was not significant. However, patients who preserved their potency tended to experience less penile shortening. Conclusions. The administration of luteinizing hormone-releasing hormone (LHRH) agonists induced significant decreases in penile length for only up to 15 months in the absence of the confounding effects of surgery and radiation.

UR - http://www.scopus.com/inward/record.url?scp=80255138399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80255138399&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2011.02364.x

DO - 10.1111/j.1743-6109.2011.02364.x

M3 - Article

C2 - 21699669

AN - SCOPUS:80255138399

VL - 8

SP - 3214

EP - 3219

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 11

ER -